Tilray Brands revenue jumps, losses narrow as it pivots away from cannabis

Tilray Brands revenue jumps, losses narrow as it pivots away from cannabis


Tilray CEO Irwin Simon: We're well positioned regardless of full U.S. legality of cannabis

Cannabis producer Tilray Brands on Wednesday reported a jump in revenue as it diversifies its portfolio and moves deeper into the beer industry.

The company reported $177 million in net revenue, up 15% year-over-year, for its fiscal first-quarter. Its cannabis division brought in $70 million in net revenue, reflecting a 20% spike year-over-year.

It also narrowed its net loss to $55.9 million during the quarter, compared with a loss of $65.8 million a year earlier.

Tilray is a multinational cannabis company based in Canada. But it has increasingly moved into other segments, particularly the U.S. craft beer industry, as it navigates an uncertain legal environment for marijuana around the world.

The company said it grew cannabis revenue in Canada by 16.5%, and strengthened its leading market share position in the country to 13.4%. Canada is one of the few major markets where recreational cannabis is legal at the federal level.

Workers inspect cannabis plants inside the grow room at the Aphria Inc. Diamond facility in Leamington, Ontario, Canada, on Wednesday, Jan. 13, 2021.

Annie Sakkab | Bloomberg | Getty Images

On an earnings call Wednesday, CEO Irwin Simon said the company’s recent beverage mergers and acquisitions will accelerate growth and expand the company’s footprint beyond its recreational cannabis business as the drug remains illegal in key markets in the world, including at the federal level in the United States and in much of Europe.

“We’re waiting for legalization to happen in the U.S.,” Simon said separately during an appearance on CNBC’s “Squawk on the Street” on Wednesday. “If it happens, it will be great and we’re well-positioned.”

If legalization in the U.S. doesn’t happen, Simon said the company will fall back on its booming beverage business.

In recent years, the company has been on a buying spree, making deals in what it said are fast-growing markets, such as craft beers and cannabis-infused beverages.

Earlier this week, Tilray completed its acquisition of eight beer brands from Anheuser-Busch InBev that it had announced over the summer. The company said the deal makes it the fifth largest in the U.S. craft beer market.

Around the same time, the company acquired the remaining 57.5% equity ownership of cannabis-infused drinks maker Truss Beverage from Molson Coors Canada.

The transaction prices of both deals were not disclosed.

Tilray’s beverage alcohol revenue jumped 17% to $24 million in its first quarter, from $21 million in the prior-year period. It cited in part growth in its Montauk Brewing Company subsidiary. Tilray acquired Montauk, a fast-growing brewer in metro New York, in 2022.

“We have strategically diversified our company globally over the past several years and, as a result, Tilray is now ideally positioned to capture a wide range of opportunities across multiple industries,” said Simon in the earnings release.



Source

The  million Trump Card faces legal challenges, limited market
Business

The $5 million Trump Card faces legal challenges, limited market

U.S. President Donald Trump holds “The Trump Card” as he speaks with journalists onboard Air Force One en route to Miami, Florida, U.S., April 3, 2025. Kent Nishimura | Reuters A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to […]

Read More
Nike will report earnings after the bell. Here’s what Wall Street expects
Business

Nike will report earnings after the bell. Here’s what Wall Street expects

A shopper walks past a Nike store, as global markets brace for a hit to trade and growth caused by U.S. President Donald Trump’s decision to impose import tariffs on dozens of countries, in the King of Prussia Mall in King of Prussia, Pennsylvania, U.S., April 3, 2025.  Rachel Wisniewski | Reuters Nike is expected […]

Read More
RFK Jr.’s CDC vaccine panel backs Merck RSV shot for infants
Business

RFK Jr.’s CDC vaccine panel backs Merck RSV shot for infants

Nikos Pekiaridis | Nurphoto | Getty Images Robert F. Kennedy Jr.’s revamped government panel of outside vaccine advisors on Thursday recommended the use of Merck‘s shot to protect infants from respiratory syncytial virus, a temporary reprieve for public health officials and companies concerned about the Health and Human Services secretary’s immunization policy. The group, called […]

Read More